Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity

Renan Carlos Castillo, Silvio Arango-Jaramillo, Rohan John, Kent Weinhold, Phyllis Kanki, Lucy Carruth, David H. Schwartz

Research output: Contribution to journalArticle

Abstract

An in vitro assay developed as a correlate of vaccine-induced protection from human immunodeficiency virus (HIV) was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. Cultures of peripheral blood mononuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1(MN) or HIV-1(BaL), titered in PBMC from normal controls (n = 57). PBMC from HIV-1-infected persons with low viremia (n = 17), exposed uninfected persons (n = 23), and HIV-2-infected Senegalese prostitutes (n = 9) were significantly resistant to HIV-1(BaL) and/or HIV-1(MN) (P <.001). Among 34 HIV vaccine recipients of live canarypox vector expressing multiple HIV-1 gene products with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to both strains (P <.001), and cytotoxic T lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples (P <.03). This is the first evidence of the induction by vaccination of a validated correlate of protection. This assay should serve as a useful criterion for assessing experimental HIV vaccines before phase III efficacy trials.

Original languageEnglish (US)
Pages (from-to)897-903
Number of pages7
JournalJournal of Infectious Diseases
Volume181
Issue number3
DOIs
StatePublished - 2000

Fingerprint

HIV-1
Immunity
Vaccines
Blood Cells
HIV
Human Immunodeficiency Virus Proteins
Sex Workers
HIV-2
Viremia
Cytotoxic T-Lymphocytes
In Vitro Techniques
Vaccination
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. / Castillo, Renan Carlos; Arango-Jaramillo, Silvio; John, Rohan; Weinhold, Kent; Kanki, Phyllis; Carruth, Lucy; Schwartz, David H.

In: Journal of Infectious Diseases, Vol. 181, No. 3, 2000, p. 897-903.

Research output: Contribution to journalArticle

Castillo, RC, Arango-Jaramillo, S, John, R, Weinhold, K, Kanki, P, Carruth, L & Schwartz, DH 2000, 'Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity', Journal of Infectious Diseases, vol. 181, no. 3, pp. 897-903. https://doi.org/10.1086/315300
Castillo, Renan Carlos ; Arango-Jaramillo, Silvio ; John, Rohan ; Weinhold, Kent ; Kanki, Phyllis ; Carruth, Lucy ; Schwartz, David H. / Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 3. pp. 897-903.
@article{4857cc5577134ecb9cd3a3615dc09f37,
title = "Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity",
abstract = "An in vitro assay developed as a correlate of vaccine-induced protection from human immunodeficiency virus (HIV) was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. Cultures of peripheral blood mononuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1(MN) or HIV-1(BaL), titered in PBMC from normal controls (n = 57). PBMC from HIV-1-infected persons with low viremia (n = 17), exposed uninfected persons (n = 23), and HIV-2-infected Senegalese prostitutes (n = 9) were significantly resistant to HIV-1(BaL) and/or HIV-1(MN) (P <.001). Among 34 HIV vaccine recipients of live canarypox vector expressing multiple HIV-1 gene products with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to both strains (P <.001), and cytotoxic T lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples (P <.03). This is the first evidence of the induction by vaccination of a validated correlate of protection. This assay should serve as a useful criterion for assessing experimental HIV vaccines before phase III efficacy trials.",
author = "Castillo, {Renan Carlos} and Silvio Arango-Jaramillo and Rohan John and Kent Weinhold and Phyllis Kanki and Lucy Carruth and Schwartz, {David H.}",
year = "2000",
doi = "10.1086/315300",
language = "English (US)",
volume = "181",
pages = "897--903",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity

AU - Castillo, Renan Carlos

AU - Arango-Jaramillo, Silvio

AU - John, Rohan

AU - Weinhold, Kent

AU - Kanki, Phyllis

AU - Carruth, Lucy

AU - Schwartz, David H.

PY - 2000

Y1 - 2000

N2 - An in vitro assay developed as a correlate of vaccine-induced protection from human immunodeficiency virus (HIV) was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. Cultures of peripheral blood mononuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1(MN) or HIV-1(BaL), titered in PBMC from normal controls (n = 57). PBMC from HIV-1-infected persons with low viremia (n = 17), exposed uninfected persons (n = 23), and HIV-2-infected Senegalese prostitutes (n = 9) were significantly resistant to HIV-1(BaL) and/or HIV-1(MN) (P <.001). Among 34 HIV vaccine recipients of live canarypox vector expressing multiple HIV-1 gene products with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to both strains (P <.001), and cytotoxic T lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples (P <.03). This is the first evidence of the induction by vaccination of a validated correlate of protection. This assay should serve as a useful criterion for assessing experimental HIV vaccines before phase III efficacy trials.

AB - An in vitro assay developed as a correlate of vaccine-induced protection from human immunodeficiency virus (HIV) was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. Cultures of peripheral blood mononuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1(MN) or HIV-1(BaL), titered in PBMC from normal controls (n = 57). PBMC from HIV-1-infected persons with low viremia (n = 17), exposed uninfected persons (n = 23), and HIV-2-infected Senegalese prostitutes (n = 9) were significantly resistant to HIV-1(BaL) and/or HIV-1(MN) (P <.001). Among 34 HIV vaccine recipients of live canarypox vector expressing multiple HIV-1 gene products with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to both strains (P <.001), and cytotoxic T lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples (P <.03). This is the first evidence of the induction by vaccination of a validated correlate of protection. This assay should serve as a useful criterion for assessing experimental HIV vaccines before phase III efficacy trials.

UR - http://www.scopus.com/inward/record.url?scp=0034073361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034073361&partnerID=8YFLogxK

U2 - 10.1086/315300

DO - 10.1086/315300

M3 - Article

C2 - 10720510

AN - SCOPUS:0034073361

VL - 181

SP - 897

EP - 903

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -